Krystal Biotech, Inc. (KRYS) has disclosed a new risk, in the Demand category. Krystal Biotech, Inc. faces significant risks related to scaling ...

周一，花旗将Krystal生物科技(NASDAQ:KRYS)的目标股价从之前的$204.00上调至$206.00。尽管如此，花旗仍维持中性评级。这一调整是在评估Krystal生物科技的销售和管理层指引后做出的。 Krystal生物科技报告其基因疗法产品Vyjuvek的销售额为$83.8百万，与花旗预估的$82.3百万和市场共识的$83.4百万基本一致。然而，花旗注意到一些令人担忧的问题，特别是患者 ...

KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.

2023年，又有四种基因治疗被批准：Vyjuvek用于大疱性表皮松解症；Lyfgenia，使用编码抗镰状血红蛋白HbAT87Q的慢病毒载体，用于镰状细胞贫血症；Casgevy，采用CRISPR-Cas9，第一… ...

Thank you for standing by and welcome to Krystal Biotech's third-quarter earnings conference call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now like to hand ...

基因疗法公司Krystal Biotech Inc. (NASDAQ: KRYS)宣布2024年第三季度实现盈利，每股收益显著增加，其主打产品VYJUVEK的收入大幅增长。在2024年11月1日的业绩电话会议上，公司概述了其成功的商业策略，包括高度关注患者和医生体验，这推动了需求和报销审批。Krystal Biotech还讨论了其临床管线的进展，并提供了在欧洲和日本扩张计划的最新情况。 要点摘要 ...

November 4, 2024Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $0.909, expectations were $0.9. Operator: Thank you for standing by and welcome to Krystal Biotech's Third Quarter ...

Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET. Company Participants. Stéphane Paquette - VP, Corporate Development Krish Krishn ...

The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare genetic disease characterised by fragile skin that can split and blister even with ...

Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023JNDA for B-VEC filed and on track for commercial ...

Goldman Sachs has started coverage of Krystal Biotech (NASDAQ:KRYS) with a buy rating, commenting that the “strong” launch execution of Krystal’s drug Vyjuvek “supports blockbuster ...

What gives this company further value is that it has already received FDA approval of a topical gel drug known as VYJUVEK. It was approved to treat wounds in patients 6 months of age and older ...